Olema Oncology (OLMA) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed Olema Oncology (OLMA) over the past year, gaining 36.1% versus a loss of 69.7%. Sagimet Biosciences Series A is the larger company by market cap ($648.0 million vs $615.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OLMA | SGMT |
|---|---|---|
| Share price | $7.02 | $9.08 |
| Market cap | $615.00M | $648.02M |
| 1-day change | -1.82% | -5.61% |
| YTD return | -71.92% | +53.38% |
| 1-year return | -69.70% | +36.13% |
| 5-year return | -66.36% | — |
| EPS (TTM) | $-2.40 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-162.45M | $-51.04M |
| 52-week high | $36.26 | $11.45 |
| 52-week low | $6.24 | $4.50 |
| Distance from 52-week high | -80.64% | -20.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +405.70% | +200.33% |
| Average volume | 1.27M | 1.23M |
| Shares outstanding | 87.61M | 71.37M |
| Employees | 131 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed OLMA by 105.8 percentage points over the past year.
About Olema Oncology
OLMA stock →Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
OLMA vs SGMT FAQ
Which is bigger, Olema Oncology or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $648.02M compared with $615.00M for Olema Oncology (OLMA).
Which stock has performed better over the past year, OLMA or SGMT?
SGMT returned +36.13% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Olema Oncology and Sagimet Biosciences Series A in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.